Nektar Therapeutics (NKTR) R&D chief sells 5,538 shares in pre-planned trade

Rhea-AI Filing Summary

Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky sold 5,538 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $60.71 per share on June 15, 2026, in multiple trades between $60.06 and $61.36.

After this sale, Zalevsky directly holds 15,437 shares of Nektar Therapeutics common stock. The transaction was carried out under a Rule 10b5-1 trading plan that he adopted on March 13, 2026, indicating the sale was pre-arranged rather than timed discretionarily.

Insights

Equity compensation and insider-trading analyst

Pre-planned open-market sale by Nektar’s R&D chief, with meaningful holdings retained.

Chief R&D Officer Jonathan Zalevsky executed an open-market sale of 5,538 shares of Nektar Therapeutics common stock at a weighted average of $60.71 on June 15, 2026. Trades occurred between $60.06 and $61.36.

The filing shows 15,437 shares directly owned after the transaction, so he continues to hold a notable equity stake. The sale was completed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, suggesting a routine liquidity event rather than an opportunistic trade.

No derivative positions are listed in the derivative summary, and the transactionSummary records a single net-sell event. Overall, this is a standard insider sale with limited informational value beyond confirming ongoing equity ownership and the existence of a trading plan.

Insider Trade Summary 10b5-1

Net Seller: 5,538 shares ($336,212)

Net Sell 1 txn

Insider Zalevsky Jonathan

Role Chief R&D Officer

Sold 5,538 shs ($336K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,538	$60.71	$336K

Holdings After Transaction: Common Stock — 15,437 shares (Direct, null)

Footnotes (1)

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. This transaction was executed in multiple trades at prices ranging from $60.06 to $61.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

Key Figures

Shares sold: 5,538 shares Weighted average sale price: $60.71 per share Post-transaction holdings: 15,437 shares +3 more

6 metrics

Shares sold 5,538 shares Open-market sale on June 15, 2026

Weighted average sale price $60.71 per share Common stock sale on June 15, 2026

Post-transaction holdings 15,437 shares Direct ownership after sale

Price range of trades $60.06–$61.36 per share Execution range for the June 15, 2026 sale

Trading plan adoption date March 13, 2026 Rule 10b5-1 plan for this sale

Net shares sold 5,538 shares transactionSummary net-sell shares

Key Terms

Rule 10b5-1 trading plan, open-market sale, weighted average sale price, multiple trades

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale of common stock by the reporting person."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

multiple trades financial

"This transaction was executed in multiple trades at prices ranging from $60.06 to $61.36."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zalevsky Jonathan

(Last) (First) (Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief R&D Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	06/15/2026		S		5,538	D	$60.71(2)	15,437	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.

2. This transaction was executed in multiple trades at prices ranging from $60.06 to $61.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

	Elizabeth Zhang, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Nektar Therapeutics (NKTR) report for Jonathan Zalevsky?

Nektar Therapeutics reported that Chief R&D Officer Jonathan Zalevsky sold 5,538 shares of common stock. The sale was an open-market transaction executed on June 15, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted earlier that year.

At what prices did Jonathan Zalevsky sell Nektar Therapeutics (NKTR) shares?

Jonathan Zalevsky’s sale was executed in multiple trades between $60.06 and $61.36 per share. The Form 4 reports a weighted average sale price of $60.71 per share for the 5,538 Nektar Therapeutics common shares sold in this transaction.

How many Nektar Therapeutics (NKTR) shares does Jonathan Zalevsky hold after this sale?

Following the June 15, 2026 transaction, Jonathan Zalevsky directly holds 15,437 shares of Nektar Therapeutics common stock. This post-transaction holding figure comes directly from the Form 4 and reflects his remaining direct ownership after the 5,538-share open-market sale.

Was the Nektar Therapeutics (NKTR) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states that Jonathan Zalevsky’s sale was made pursuant to a Rule 10b5-1 trading plan. The plan was adopted on March 13, 2026, indicating the trade was pre-scheduled rather than a discretionary decision based on short-term market movements.

Did the Nektar Therapeutics (NKTR) Form 4 disclose any derivative securities for Jonathan Zalevsky?

No derivative securities are listed in the derivative summary for this Form 4. The reported activity covers only a non-derivative transaction: an open-market sale of 5,538 shares of Nektar Therapeutics common stock, with 15,437 shares shown as directly owned afterward.